II. Indications
III. Contraindications
- Cardiovascular Disease
IV. Dosing: Adult
-
Hyperprolactinemia
- Start: 0.25 orally twice weekly
- Titrate: Increase by 0.25 mg every month up to 1 mg twice weekly
- Follow Serum Prolactin levels
- May stop Cabergoline after Serum Prolactin normal for 6 months
-
Acromegaly (not FDA approved)
- Start 0.5 mg orally twice weekly
- Base titration on plasma IGF1 Levels
- May increase up to 3.5 mg/dose each week as needed
V. Pharmacokinetics
- Hepatic metabolism
VI. Adverse Effects
- Fewer adverse effects than Bromocriptine (but less observational data in pregnancy)
- Safety
- Pregnancy Category B
- Avoid in Lactation
- Nausea or Vomiting
- Postural Hypotension
- Dizziness
- Headache
- Sedation
- Hypersexuality and Compulsive Gambling (risk with most Dopamine Agonists)
- Valvular disorders
- Reported with high dose Cabergoline (>4 mg daily)
- Follow Echocardiogram every 6 to 12 months
- Fibrosis
- Pleural fibrosis
- Retroperitoneal fibrosis
- Cardiac fibrosis
VII. Resources
VIII. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- Huang (2012) Am Fam Physician 85(11): 1073-80 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
| cabergoline (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| CABERGOLINE 0.5 MG TABLET | Generic | $2.01 each |